[Oral therapy in type 2 diabetes. Critical evaluation of glitazones].
Lotz
N
N
Herz- und Diabeteszentrum NRW, Klinik der Ruhr-Universität Bochum, Georgstr. 11, D-32545 Bad Oeynhausen. nlotz@hdz-nrw.de
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D017277:Drug Approval; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007333:Insulin Resistance / Q000502:physiology; D000077205:Pioglitazone; D018160:Receptors, Cytoplasmic and Nuclear / Q000187:drug effects; D000077154:Rosiglitazone; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D045162:Thiazolidinediones; D014157:Transcription Factors / Q000187:drug effects
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D045162:Thiazolidinediones; D014157:Transcription Factors; D000077154:Rosiglitazone; D000077205:Pioglitazone